ASCO Selects 28 Sarah Cannon Studies for Presentation at Annual Meeting
The meeting, which takes place May 31-June 3 in Chicago, attracts more than 30,000 cancer specialists and is considered the premier oncology research conference in the world.
"Having two-thirds of our 41 submitted papers accepted for presentation is an outstanding achievement," said Dee Anna Smith, SCRI chief executive officer. "Our researchers are passionate about improving patient care and finding new and more effective cancer treatments."
Two of the abstracts were chosen for oral presentation at a clinical science symposium, indicating that these research studies are among the best at the conference. One of the studies will be presented by SCRI Chief Scientific Officer John Hainsworth, M.D., and is a Phase II trial of a new combination of targeted agents (everolimus/bevacizumab) in the treatment of patients with advanced clear cell renal carcinoma. The other study will be presented by SCRI Investigator of Drug Development and GI Cancer Research Jeffrey Infante, M.D. and is a Phase I trial of a novel targeted agent (AZD4877) in the treatment of patients with refractory solid tumors.
The remaining studies focus on the efficacy of new combinations of medications and radiation in the treatment of breast, lung and gastrointestinal cancers, lymphoma and refractory malignancies. There are 14 abstracts that will be presented at general poster sessions and 12 that are included in poster discussion sessions.
SCRI principal investigators presenting include Howard A. Burris III, M.D.; John D. Hainsworth, M.D.; F. Anthony Greco, M.D.; Denise A. Yardley, M.D.; David R. Spigel, M.D.; Suzanne F. Jones, Pharm.D.; and Jeffrey R. Infante, M.D. The study findings were completed through the collaborative effort of physician researchers across SCRI's community-based network in 23 states.
About ASCO
The ASCO annual meeting is an international gathering of physicians, academicians, clinical researchers and other healthcare professionals involved in multidisciplinary clinical cancer care. ASCO's objectives are to advance the education of physicians and other professionals caring for patients with cancer, to support the development of clinical cancer researchers and to facilitate the delivery of high-quality healthcare to patients with cancer.
About SCRI
SCRI is one of the largest clinical research programs in the nation, conducting community-based clinical trials in oncology and other therapeutic areas through affiliations with a network of nearly 500 physicians in 23 states. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites across the country.
Contact
Sarah Cannon Research Institute
Anna Walker, 615-329-7216
Anna.Walker@scresearch.net
Posted: May 2008
